Researchers recently investigated antenatal betamethasone outcomes in children born during the late preterm period. This follow-up study examined participants from the landmark Antenatal Late Preterm Steroids (ALPS) trial. Specifically, the medical team assessed respiratory health in children aged six years or older. Many clinicians currently debate the necessity of steroids for deliveries occurring between 34 and 36 weeks of gestation. Therefore, these long-term results provide critical guidance for modern obstetric practice and parental counseling.
Long-Term Antenatal Betamethasone Outcomes
The study analyzed over 1,200 children to determine the safety profile of the treatment. Notably, the primary respiratory composite showed no significant difference between the betamethasone and placebo groups. This composite included factors such as abnormal spirometry results and physician-diagnosed asthma. Consequently, clinicians can reassure families regarding the long-term safety of this common intervention. However, children in the betamethasone group actually reported less frequent whistling or wheezing in the chest compared to the placebo group. This suggests a potential protective effect against certain mild respiratory symptoms.
Spirometry and Lung Function Results
Furthermore, the researchers compared the ALPS children to a term reference cohort for context. Interestingly, children born late preterm showed more exercise-induced wheezing than infants born at full term. This finding suggests that gestational age at birth influences respiratory health more than the steroid exposure does. Moreover, the spirometry data remained highly consistent across both randomized groups in the trial. Additionally, the treatment did not increase the risk of chronic lung disease or the need for daily medications. Thus, the immediate benefits of steroid use do not appear to come at a long-term respiratory cost. Obstetricians should continue to discuss these findings with patients facing a risk of late preterm delivery. Ultimately, the study supports the safe use of betamethasone in this specific gestational window.
Frequently Asked Questions
Q1: Does late preterm betamethasone use affect childhood lung function?
No, the follow-up data shows that children who received betamethasone have spirometry results similar to those who received a placebo. Researchers observed no significant differences in lung function tests at age six or older.
Q2: Does the treatment reduce the risk of asthma in children?
The study found no difference in the rates of physician-diagnosed asthma or the use of daily asthma medications. However, children in the betamethasone group experienced lower rates of wheezing and whistling in the chest compared to the placebo group.
References
- Gyamfi-Bannerman C et al. Childhood Pulmonary Outcomes After Late Preterm Antenatal Corticosteroids. Obstet Gynecol. 2026 Mar 01. doi: 10.1097/AOG.0000000000006162. PMID: 41570323.
- Gyamfi-Bannerman C, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016;374(14):1311-1320.
- Roberts D, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454.